West Pharmaceutical Services, Inc. (NYSE:WST) produced a 43.84% rally since recording the worst price of $72.34. Thanks to the latest 10.13% increase, it now trades at $100.93. Throughout the trading on 10/26/2017, the share price floated between $98.14 and $103.36. This company shares are -2.76% up from its target price of $98.14 and the current market capitalization stands at $7.46B. The recent change has given its price a 10.21% lead over SMA 50 and 1.02% lead over its 52-week high. The stock witnessed 5.43% gains, 12.71% gains and 9.67% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found WST’s volatility during a week at 2.33% and during a month it has been found around 1.84%.West Pharmaceutical Services, Inc. (WST) Top Holders
Institutional investors currently hold around $6.24 billion or 92.9% in WST stock. Look at its top three institutional owners. Price T Rowe Associates Inc /Md/ owns $851.09 million in West Pharmaceutical Services, Inc., which represents roughly 11.41% of the company’s market cap and approximately 13.64% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 6,555,351 shares of the stock are valued at $600.8 million. The third largest holder is Blackrock Inc., which currently holds $569.87 million worth of this stock and that ownership represents nearly 7.64% of its market capitalization.West Pharmaceutical Services, Inc. 13F Filings
At the end of 06/30/2017 reporting period, 184 institutional holders increased their position in West Pharmaceutical Services, Inc. (NYSE:WST) by some 4,894,150 shares, 118 decreased positions by 4,718,286 and 36 held positions by 58,486,046. That puts total institutional holdings at 68,098,482 shares, according to SEC filings. The stock grabbed 43 new institutional investments totaling 1,369,862 shares while 27 institutional investors sold out their entire positions totaling 161,403 shares.West Pharmaceutical Services, Inc. (NYSE:WST) Insider Trades
Multiple company employees have indulged in significant insider trading. West Pharmaceutical Services, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Sr. VP & CFO Federici William J has sold 54,996 shares of West Pharmaceutical Services, Inc. (WST) in trading session dated May. 18, 2017. These shares are worth $5,249,368 and were traded at $95.45 each. The SEC filing shows that Malone Daniel performed a sale of 4,124 shares. The Vice President & Controller disposed these shares by way of transaction on May. 02, 2017. The company’s shares were given away at $93.31 per share worth to an income of some $384,810 on account of Malone Daniel.
Director, Zenner Patrick J, purchased 332 common shares of West Pharmaceutical Services, Inc. (WST) in the open market. In a transaction dated Dec. 08, 2016, the shares were bought at an average price of $84.53, giving away a sum of $28,064. After this purchase, 51,831 common shares of WST are directly owned by the insider, with total stake valued at $5,231,303.
In the transaction dated Oct. 31, 2016, the great number of shares disposed came courtesy the Director; Johnson Paula A disposed a total of 2,466 shares at an average price of $75.87, amounting to approximately $187,095. The insider now directly owns 36,038 shares worth $3,637,315.West Pharmaceutical Services, Inc. (WST) Analyst Guide
Several analysts have released their opinion on West Pharmaceutical Services, Inc. (NYSE:WST), with 3 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.8 average brokerage recommendation.